SPRY2, sprouty RTK signaling antagonist 2, 10253

N. diseases: 111; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 AlteredExpression phenotype BEFREE Our results indicated that SPRY2 overexpression is associated with human oral squamous-cell carcinogenesis. 29291435 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 Biomarker phenotype BEFREE The present study confirms and extends the previous reports through indicating transcript-specific down-regulation and significant association of DAB2IP and SPRY2 in prostate tumorigenesis. 30301636 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 Biomarker phenotype BEFREE Additionally, spry2 inhibited the tumorigenesis and angiogenesis of MM cells in vivo. 27016275 2016
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 Biomarker phenotype BEFREE SPROUTY2 (SPRY2) is an intracellular regulator of receptor tyrosine kinase signaling involved in cell growth, differentiation and tumorigenesis. 23624922 2014
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 Biomarker phenotype BEFREE In murine prostate cancer models, Pten haploinsufficiency synergized with Spry2 deficiency to drive tumorigenesis, including metastasis. 23434594 2013
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 Biomarker phenotype BEFREE Inhibition of microRNA-21 (mir‑21) induced upregulation of Spry2 and PTEN which underscores the importance of mir-21 in Spry2-associated tumorigenesis of the colon. 22322462 2012
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 Biomarker phenotype BEFREE In vitro experiments and mice models have confirmed the importance of Sprouty 2 (Spry2) in inhibiting tumorigenesis and the progression of human cancer. 22484587 2012
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 Biomarker phenotype BEFREE Spry2 inhibited the growth and tumorigenesis of colon cancer cells in vivo. 21099344 2011
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.090 PosttranslationalModification phenotype BEFREE Hence, while biallelic epigenetic inactivation of hSPRY2 represents the main genetic event in prostate carcinogenesis, the observed 27-40% LOH presents evidence of hemizygous deletion with the remaining allele hypermethylated. 15735753 2005